News

NewtekOne, Inc. Anticipates $1.4 Billion in Business Loans

NewtekOne, Inc. Anticipates $1.4 Billion in Business Loans

NewtekOne's Ambitious Loan Goals for 2024

NewtekOne, Inc. (NASDAQ: NEWT) has set its sights on a remarkable goal for the coming year, aiming to originate an impressive $1.4 billion in business loans across various lending products. This includes popular offerings such as SBA 7(a) and SBA 504 loans, as well as alternative loan programs, commercial real estate (CRE) conforming loans, and commercial & industrial (C&I) conforming loans. Furthermore, the company anticipates a significant growth trajectory, projecting approximately $1.9 billion in business loans for 2025, representing a phenomenal 36% increase compared to its 2024 forecast.

Understanding Loan Predictions and Categories

In 2024, the breakdown of NewtekOne's loan origination targets highlights key categories driving its business. Notably, the alternative loan program, along with the CRE and C&I loans, is expected to fuel the most growth. The recent structural changes within the company have led to SBA 7(a) loans being exclusively originated by Newtek Bank, N.A. As a result, the growth in these loans should be viewed from a historical perspective while ensuring clients receive the best possible service.

A Look at the Loan Categories

The company has clearly defined its loan origination objectives for 2024 and 2025, with details for each category illustrating their commitment to transparency and accountability:

  • SBA 7(a): 2024 target of $935 million and 2025 projection of $1 billion.
  • SBA 504: Expected to increase significantly from $125 million in 2024 to $250 million in 2025.
  • Alternative Loan Program Loans: An ambitious doubling from $250 million to $500 million expected in two years.
  • CRE Conforming Loans: From $60 million to $100 million, marking a strong growth rate.
  • C&I Conforming Loans: Growing from $35 million in 2024 to $60 million in 2025.

The Strategy Behind Successful Loan Origination

Barry Sloane, President, Chairman, and CEO of NewtekOne, articulated the company's approach to achieving these forecasts. He emphasized the importance of maintaining a controlled, diversified lending environment. The objective is to offer borrowers unique features typically not found in traditional financial institutions—such as extended amortization schedules without balloon payments. This innovative strategy allows clients more manageable financial responsibilities while offering full personal guarantees to ensure safety for NewtekOne's lending practices.

Client-Centric Approach

NewtekOne prides itself on a frictionless experience for clients, leveraging technology to streamline the lending process. With a staggering 600 to 900 business referrals daily, the company draws from a vast network of independent businesses seeking financial support. This level of engagement ensures that diverse financing solutions are readily available, catering to unique client needs.

Looking Forward: A Vision for the Future

As NewtekOne continues to advance in the competitive landscape of business financing, its focus remains on diversification—spreading risk across various industries and loan types. The strategic direction aligns with the company’s ethos of serving independent businesses throughout the nation. By meeting the demands of its extensive network, NewtekOne not only enhances customer satisfaction but also positions itself as a leader in the lending space, defying the norms of the typical commercial financial institution.

The Importance of Risk Management

With over 20 years of experience in loan servicing and a robust portfolio exceeding $3.5 billion, NewtekOne emphasizes prudent risk management through diverse credit exposure. This capability harnesses industry knowledge and experience, allowing the company to navigate both favorable and challenging economic environments confidently. The management team maintains rigorous standards to anticipate and mitigate potential losses, reinforcing the company's stability and reliability.

Frequently Asked Questions

What is NewtekOne's loan origination target for 2024?

NewtekOne, Inc. aims to originate approximately $1.4 billion in business loans across multiple products for 2024.

How much does NewtekOne project for loan origination in 2025?

For 2025, the company projects about $1.9 billion in loan originations, representing a 36% increase from 2024.

What loan products does NewtekOne offer?

NewtekOne offers several loan products, including SBA 7(a) loans, SBA 504 loans, alternative loans, and various conforming loans.

What strategies does NewtekOne use to mitigate risk?

NewtekOne employs diversification across industries and loan types, along with structured personal guarantees and risk allocation techniques.

How does NewtekOne position itself within the lending market?

The company emphasizes a customer-centric approach and innovative loan offerings, differentiating itself from typical fintech and commercial lenders.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading

Top 5 Most Recently Viewed Articles

A Comprehensive Look at Apple's Competitive Position in Tech

Updated Category News Views 313

Understanding Apple's Competitive Landscape In today's dynamic business environment, a deep-dive analysis of top companies is essential for investors and industry insiders. This examination will focus on Apple (AAPL), alongside its chief rivals in the Technology Hardware, Storage & Peripherals sector. By analyzing crucial financial indicators, market positioning, and...

Continue Reading
Cegedim Shares Insights on Latest Liquidity Contract Performance

Updated Category News Views 135

Overview of Cegedim's Liquidity Contract Statement This article covers the latest updates on Cegedim’s liquidity contract performance, highlighting significant figures and trends that reflect the company's financial health. Cegedim has established a robust liquidity contract with Rothschild Martin Maurel, aimed at promoting transparency and liquidity in its shares. Key...

Continue Reading
Silexion Therapeutics Advances SIL204 for Pancreatic Cancer

Updated Category News Views 136

Silexion Therapeutics Moves Forward with SIL204 Silexion Therapeutics Corp. (NASDAQ: SLXN) is celebrating a significant milestone with the completion of crucial toxicology studies for its innovative RNA silencing therapy, SIL204. This groundbreaking therapy, designed to target mutated KRAS oncogenes, has shown no signs of systemic organ toxicity, reinforcing the...

Continue Reading
Emerson Partners with LifeSight for Enhanced Pension Solutions

Updated Category News Views 178

Emerson Partners with LifeSight for Pension Solutions LifeSight, WTW’s UK defined contribution (DC) master trust, has stepped into a significant role by becoming the full master trust provider for Emerson, the advanced electronics powerhouse. This partnership aims to cover all active, deferred, and drawdown members effectively, ensuring they are well-accommodated in...

Continue Reading
Howard Marks Joins Alliance for Decision Education Board

Updated Category News Views 227

Exciting News from the Alliance for Decision Education The Alliance for Decision Education is thrilled to announce an important addition to its Board of Directors. Howard Marks, a leader in investment management and a well-respected voice in decision-making, has agreed to join the board. As the co-chairman and co-founder of Oaktree Capital Management, Marks brings with...

Continue Reading